Positive DARRT-1 Data in Late-Stage Prostate Cancer

NEXT STORY
Mateon Therapeutics Team Publishes Three New Peer-Reviewed Oncology Articles Outlining the Clinical Impact Potential of Its First-In-Class Anti-TGF-Beta RNA Therapeutic OT101/Trabedersen
PREV STORY
Fortress Biotech to Participate in December 2019 Investor Conferences
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global Immunoassay Markets (2021 to 2025) – by Instrument Type, Application and Country

author_avatar
NASDAQ Market News

Merus legt auf dem San Antonio Breast Cancer Symposium neue Ergebnisse zu Zenocutuzumab, Trastuzumab und Vinorelbin bei Patientinnen mit HER2-verstärktem metastasierendem Brustkrebs vor

author_avatar
NASDAQ Market News

Aadi Reports Third Quarter 2021 Financial Results and Provides Business Update

author_avatar
NASDAQ Market News